ENSO price fluctuated by 60.5% in the past 24 hours (high of $1.36): Trading volume soared over 100 times, driving speculative surge
Bitget Pulse2026/04/26 22:54Volatility Overview
ENSO's price surged from a low of $0.8475 to a high of $1.36 over the past 24 hours, currently quoted at $0.9894, with a price swing amplitude of 60.5%. The 24-hour trading volume skyrocketed to around $270-340 million, soaring over 100 times compared to the previous day, and net capital outflow reached about $1.04 million (mainly on CEX).
Brief Analysis of the Abnormal Movement
- Explosive Growth in Trading Volume: Within 24 hours, trading volume surged over 100 times from low levels, driving the price to rebound from a low of $0.785 to a high of $1.1013. This mainly occurred on Binance and Bybit spot markets, with multiple volume spikes reaching several hundred thousand USDT within 15 minutes.
- Surge in Retail Speculative Interest: The price increased by 14.5%–42.7%, far exceeding the overall market, mainly driven by retail speculation. There were several gains of 20%–28.7% within an hour, without any clear official announcements or large whale transactions on-chain.
Market Opinions and Outlook
The community sentiment is leaning bullish, with traders focusing on Binance spot volume spikes as "pump" signals. However, there is a general warning of short-term pullback risk, and it's advised to wait for confirmation of support at $0.819–0.831 before entering long positions. The mainstream view holds that momentum remains strong, and if the broader market doesn't drag the price down, it could continue to test resistance at $0.95–1.00, although high volatility could easily trigger a pullback.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

Crypto: In 2026, BNB Chain Emerges as the Global Leader in RWA Growth

BlackRock Bitcoin ETF outflows hit $19.23M as sector sheds $463M in four days
Pi Network Price Prediction: Can PI Hold Its Wedge Breakout Before the Upgrade?
